Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target

Published 12/03/2025, 12:58
Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target

On Wednesday, Deutsche Bank (ETR:DBKGn) analyst Emmanuel Papadakis upgraded argenx SE (ARGX:BB) (NASDAQ: ARGX) stock from Sell to Hold. The new price target is set at EUR575.00. Papadakis provided insight into the decision, noting a change in market conditions and a reevaluation of the company’s future outlook.

The analyst had previously downgraded argenx in mid-January due to concerns that the stock’s valuation had become over-inflated. At that time, the anticipation for clinical catalysts was low, and the focus was on commercial execution. This was after two strong chronic inflammatory demyelinating polyneuropathy (CIDP) launch quarters, which had already heightened expectations, as evidenced by the lackluster market reaction to a solid fourth-quarter performance announced in early January.

Since the downgrade, argenx’s stock has experienced a 20% decline from its peak on January 14, with American Depositary Receipts (ADRs) falling 15% compared to a 3% rise in the Nasdaq Biotechnology Index (NBI). Papadakis highlighted that this underperformance was not unique to argenx, as similar European small and mid-cap (smid) peers, like UCB, also saw comparable declines of around 10% during the same period.

The analyst pointed out that the recent market dislocation, along with a reassessment of argenx’s fiscal year 2025 outlook, contributed to the revised rating. The competitive data points that were emphasized in the January downgrade have also been considered in the context of the current market environment.

The upgrade to Hold reflects a shift in Deutsche Bank’s stance on argenx, suggesting a more neutral outlook for the company’s shares moving forward. The new price target of EUR575.00 offers a reference point for investors against the backdrop of recent market dynamics and the company’s commercial and competitive landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.